Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QDFS | ISIN: US86627T1088 | Ticker-Symbol:
NASDAQ
20.05.24
21:59 Uhr
4,540 US-Dollar
0,000
0,00 %
1-Jahres-Chart
SUMMIT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SUMMIT THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SUMMIT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.05.Summit Therapeutics Inc. - 8-K, Current Report1
02.05.Earnings call: Summit Therapeutics reports on ivonescimab trials3
01.05.Summit Therapeutics Inc reports results for the quarter ended in March - Earnings Summary2
01.05.Summit Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
01.05.Summit Therapeutics Inc. - 8-K, Current Report1
01.05.Summit Therapeutics Inc. - 10-Q, Quarterly Report1
01.05.Summit Therapeutics Non-GAAP EPS of -$0.05 beats by $0.011
01.05.Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 202452MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the...
► Artikel lesen
29.04.Summit Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview1
11.04.Summit Therapeutics Inc. - 8-K, Current Report1
09.04.Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed40
09.04.Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor24
03.04.Summit Therapeutics Inc. - 8-K, Current Report1
29.03.Why Summit Therapeutics Stock Crushed the Market This Week4
26.03.Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment9
25.03.Summit Therapeutics stock gets buy rating, $8 target on ivonescimab potential1
22.03.Summit Therapeutics Inc. - 8-K, Current Report1
14.03.Summit Therapeutics Inc.: Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024279Two Poster Presentations Will Feature Updated Ivonescimab Data from the AK112-201 and AK112-202 Phase II Studies in Advanced or Metastatic NSCLC Patient Populations Posters to be Presented by...
► Artikel lesen
05.03.Summit Therapeutics Inc. - 8-K, Current Report2
21.02.Earnings call: Summit Therapeutics outlines ivonescimab's progress and financial health2
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1